Additional investigation is necessary to elucidate the therapeutic effects of targeting CNBP/SMARCC2 in TH‐MYCN transgenic or immunocompetent mice, while quantitative proteomics are helpful in exploring additional CNBP protein partners in tumour progression. The gene discussed is SMARCC2; the disease is neoplasm.